Showing 41-50 of 2105 results for "".
Improving Your After-Tax Financial Efficiency
https://practicalneurology.com/columns/practice-management/improving-your-after-tax-financial-efficiency/30377/Discontinuing Disease-Modifying Therapy in Multiple Sclerosis: Should You Have an Exit Strategy?
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/discontinuing-disease-modifying-therapy-in-multiple-sclerosis-should-you-have-an-exit-strategy/30303/Two experts sound off on the implications of indefinite treatment and whether DMTs should be stopped.Seven Reasons to Review Your Life Insurance Plan
https://practicalneurology.com/columns/practice-management/seven-reasons-to-review-your-life-insurance-plan/30333/Life insurance plans cannot be refinanced like mortgage plans, but they can be replaced.Dementia Caregiver Needs
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/dementia-caregiver-needs/31802/Caregiver needs exist and can be addressed at all stages of the dementias.MS Minute: Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease/32180/MOGAD, an inflammatory demyelinating disease of the central nervous system, has some overlapping clinical features with NMOSD and MS but is a distinct entity with unique pathologic, clinical, and imaging features.Neuromuscular Notes: Next Generation Treatments for Myasthenia Gravis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/neuromuscular-notes-next-generation-treatments-for-myasthenia-gravis/31666/Complement inhibitors, FcRn antagonists, and B-cell targeted therapies increase treatment options for MG but do not replace existing immunosuppressive therapies.Microplastics and "Negative Neuroplasticity": An Emerging Topic in Clinical Neurology
https://practicalneurology.com/columns/practice-management/microplastics-and-negative-neuroplasticity/39811/Microplastics are neurotoxic in nature and can enter and accumulate in the brain, raising many questions concerning their role in common neurologic illnesses.Neuromodulation Strategies for Lennox-Gastaut Syndrome: A New Frontier
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/neuromodulation-strategies-for-lennox-gastaut-syndrome-a-new-frontier/39964/The evolution of neuromodulation strategies for the management of Lennox- Gastaut syndrome emphasizes the role of targeted thalamic stimulation, the importance of individualized approaches, and the need for further research to optimize treatment efficacy.A 70-Year-Old Man with a Sudden Lisp
https://practicalneurology.com/diseases-diagnoses/tbi/a-70-year-old-man-with-a-sudden-lisp/30515/Facial Twitching Progressing to More Bothersome Symptoms in a 42-Year-Old Man
https://practicalneurology.com/columns/practice-management/facial-twitching-progressing-to-more-bothersome-symptoms-in-a-42-year-old-man/30730/